These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 30661841)

  • 1. Increased bilirubin levels in Parkinson's disease.
    Macías-García D; Méndez-Del Barrio C; Jesús S; Labrador MA; Adarmes-Gómez A; Vargas-González L; Carrillo F; Gómez-Garre P; Mir P
    Parkinsonism Relat Disord; 2019 Jun; 63():213-216. PubMed ID: 30661841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased bilirubin levels in de novo Parkinson's disease.
    Moccia M; Picillo M; Erro R; Longo K; Amboni M; Santangelo G; Palladino R; Allocca R; Caporale O; Triassi M; Pellecchia MT; Barone P; Vitale C
    Eur J Neurol; 2015 Jun; 22(6):954-9. PubMed ID: 25740378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lower Serum Bilirubin and Uric Acid Concentrations in Patients with Parkinson's Disease in China.
    Qin XL; Zhang QS; Sun L; Hao MW; Hu ZT
    Cell Biochem Biophys; 2015 May; 72(1):49-56. PubMed ID: 25449297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parkinson's Disease is Accompanied by Intertwined Alterations in Iron Metabolism and Activated Immune-inflammatory and Oxidative Stress Pathways.
    de Farias CC; Maes M; Bonifacio KL; Matsumoto AK; Bortolasci CC; Nogueira AS; Brinholi FF; Morimoto HK; de Melo LB; Moreira EG; Barbosa DS
    CNS Neurol Disord Drug Targets; 2017; 16(4):484-491. PubMed ID: 28240188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum glutathione peroxidase, xanthine oxidase, and superoxide dismutase activities and malondialdehyde levels in patients with Parkinson's disease.
    Gökçe Çokal B; Yurtdaş M; Keskin Güler S; Güneş HN; Ataç Uçar C; Aytaç B; Durak ZE; Yoldaş TK; Durak İ; Çubukçu HC
    Neurol Sci; 2017 Mar; 38(3):425-431. PubMed ID: 27900485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping.
    An H; Zeng X; Niu T; Li G; Yang J; Zheng L; Zhou W; Liu H; Zhang M; Huang D; Li J
    J Neurol Sci; 2018 Mar; 386():46-52. PubMed ID: 29406966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impairment of dynamic thiol-disulphide homeostasis in patients with idiopathic Parkinson's disease and its relationship with clinical stage of disease.
    Vural G; Gumusyayla S; Bektas H; Deniz O; Alisik M; Erel O
    Clin Neurol Neurosurg; 2017 Feb; 153():50-55. PubMed ID: 28027505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serological profiles of urate, paraoxonase-1, ferritin and lipid in Parkinson's disease: changes linked to disease progression.
    Ikeda K; Nakamura Y; Kiyozuka T; Aoyagi J; Hirayama T; Nagata R; Ito H; Iwamoto K; Murata K; Yoshii Y; Kawabe K; Iwasaki Y
    Neurodegener Dis; 2011; 8(4):252-8. PubMed ID: 21282940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased plasma bilirubin in Parkinson patients on L-dopa: evidence against the free radical hypothesis?
    Scigliano G; Girotti F; Soliveri P; Musicco M; Radice D; Caraceni T
    Ital J Neurol Sci; 1997 Apr; 18(2):69-72. PubMed ID: 9239525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphocyte vitamin C levels as potential biomarker for progression of Parkinson's disease.
    Ide K; Yamada H; Umegaki K; Mizuno K; Kawakami N; Hagiwara Y; Matsumoto M; Yoshida H; Kim K; Shiosaki E; Yokochi T; Harada K
    Nutrition; 2015 Feb; 31(2):406-8. PubMed ID: 25592020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma oxidative and inflammatory markers in patients with idiopathic Parkinson's disease.
    Andican G; Konukoglu D; Bozluolcay M; Bayülkem K; Firtiına S; Burcak G
    Acta Neurol Belg; 2012 Jun; 112(2):155-9. PubMed ID: 22426659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron and Oxidative Stress in Parkinson's Disease: An Observational Study of Injury Biomarkers.
    Medeiros MS; Schumacher-Schuh A; Cardoso AM; Bochi GV; Baldissarelli J; Kegler A; Santana D; Chaves CM; Schetinger MR; Moresco RN; Rieder CR; Fighera MR
    PLoS One; 2016; 11(1):e0146129. PubMed ID: 26751079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relation of serum uric acid levels with L-Dopa treatment and progression in patients with Parkinson's disease.
    Vieru E; Köksal A; Mutluay B; Dirican AC; Altunkaynak Y; Baybas S
    Neurol Sci; 2016 May; 37(5):743-7. PubMed ID: 26753800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of novel biomarkers for Parkinson's disease by metabolomic technologies.
    Hatano T; Saiki S; Okuzumi A; Mohney RP; Hattori N
    J Neurol Neurosurg Psychiatry; 2016 Mar; 87(3):295-301. PubMed ID: 25795009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of salivary heme oxygenase-1 as a potential biomarker of early Parkinson's disease.
    Song W; Kothari V; Velly AM; Cressatti M; Liberman A; Gornitsky M; Schipper HM
    Mov Disord; 2018 Apr; 33(4):583-591. PubMed ID: 29488275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased serum proNGF concentration in patients with Parkinson's disease.
    Xu XM; Dong MX; Feng X; Liu Y; Pan JX; Jia SY; Cao D; Wei YD
    Neurol Sci; 2018 Jan; 39(1):91-96. PubMed ID: 29052090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association of low levels of nesfatin-1 and glucagon-like peptide-1 with oxidative stress in Parkinson's disease.
    Emir GK; Ünal Y; Yılmaz N; Tosun K; Kutlu G
    Neurol Sci; 2019 Dec; 40(12):2529-2535. PubMed ID: 31280388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidative stress in skin fibroblasts cultures from patients with Parkinson's disease.
    del Hoyo P; García-Redondo A; de Bustos F; Molina JA; Sayed Y; Alonso-Navarro H; Caballero L; Arenas J; Agúndez JA; Jiménez-Jiménez FJ
    BMC Neurol; 2010 Oct; 10():95. PubMed ID: 20958999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythrocyte antioxidant enzymes in Parkinson's disease.
    Abraham S; Soundararajan CC; Vivekanandhan S; Behari M
    Indian J Med Res; 2005 Feb; 121(2):111-5. PubMed ID: 15756044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The range and nature of sleep dysfunction in untreated Parkinson's disease (PD). A comparative controlled clinical study using the Parkinson's disease sleep scale and selective polysomnography.
    Dhawan V; Dhoat S; Williams AJ; Dimarco A; Pal S; Forbes A; Tobías A; Martinez-Martin P; Chaudhuri KR
    J Neurol Sci; 2006 Oct; 248(1-2):158-62. PubMed ID: 16780888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.